A time-series analysis of the use of opioid medications in a network of Brazilian hospitals, 2009-2020

2009-2020年巴西某医院网络中阿片类药物使用情况的时间序列分析

阅读:1

Abstract

BACKGROUND: To date, no studies in Brazil have described the profile of hospital opioid use. This study aimed to describe the temporal evolution of opioid consumption in hospitalised patients in a Brazilian hospital network. METHODS: This study describes a 12-year time-series (2009-2020) of hospital use of opioids in 28 hospitals of a private network in Brazil. More than four million prescriptions were analyzed using the Joinpoint Regression Program. FINDINGS: Parenteral tramadol was the most consumed opioid, followed by parenteral fentanyl and parenteral morphine. Among enteral opioids, the most commonly used was codeine followed by tramadol. There were several variations in the use patterns for most medications, with periods of significant increases and decreases, but two opioids underwent considerable change: parenteral fentanyl, which doubled in consumption, especially during the COVID-19 pandemic, and enteral tramadol, which had a fourfold reduction over time. Enteral oxycodone, the pivot of the opioid crisis in the USA, was relatively little used in this series. Methadone, both parenteral and enteral, was seldom used at the hospitals under analysis, an indicator of a mild use of other opioids, before and/or during hospitalisation. INTERPRETATION: Knowledge and documentation of the utilisation profile of this class of medication is relevant, given the concern that any increase in consumption at any point in the chain, including during hospitalisations, may trigger events of increased outpatient opioid use and potential misuse. FUNDING: Carlos Chagas Filho Foundation for Research Support in the State of Rio de Janeiro (FAPERJ, grant E-26/010.002428/2019) and IDORDepartment of Pediatrics, Rio de Janeiro, RJ, Brazil.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。